ST诺泰涨0.37%，成交额7379.64万元，今日主力净流入238.37万

Core Viewpoint - ST诺泰 is experiencing a positive market response with a slight increase in stock price and significant trading volume, indicating investor interest in the company's growth potential in the pharmaceutical sector [1]. Group 1: Business Overview - The company specializes in custom products, primarily through its CDMO (Contract Development and Manufacturing Organization) business, which emphasizes the integration of high-tech process development and large-scale production capabilities [2]. - ST诺泰's product portfolio includes Thymosin Alpha 1 for chronic hepatitis B treatment and a GLP-1 receptor agonist (SPN0103-009) for diabetes and weight loss, which has received clinical trial approval [3]. - The company has also received approval for Oseltamivir Phosphate capsules, an antiviral medication for treating and preventing influenza in adults and children [4]. Group 2: Financial Performance - For the year 2024, overseas revenue accounts for 63.12% of total revenue, benefiting from the depreciation of the Chinese yuan [4]. - In the first nine months of 2025, ST诺泰 reported revenue of 1.527 billion yuan, a year-on-year increase of 21.95%, and a net profit of 445 million yuan, up 26.92% compared to the previous year [8]. Group 3: Market Activity - The stock has seen a net inflow of 2.3837 million yuan today, with a slight increase in institutional investment over the past two days, although the overall industry has experienced a net outflow [5][6]. - The average trading cost of the stock is 41.23 yuan, with recent buying activity indicating potential accumulation, although the strength of this accumulation is not strong [7].